Crisil upgrades Metropolis Healthcare outlook to positive, reaffirms AA- rating
Crisil cited stronger organic growth, margin performance and the turnaround at Core Diagnostics in revising Metropolis Healthcare’s outlook. The diagnostics chain reported FY26 revenue of ₹1,646 crore and continues to expand its North India footprint while maintaining low debt and strong liquidity.
What happened
Crisil upgraded Metropolis Healthcare’s outlook to positive while retaining its AA- rating, citing stronger organic growth, margins and Core Diagnostics
Key facts
- Crisil AA-
- Crisil A1+
- 24% revenue growth
- ₹1,646 crore FY26 revenue
- 16.6% Q1 FY27 revenue growth
What changed
Crisil upgraded Metropolis Healthcare’s outlook to positive while retaining its AA- rating, citing stronger organic growth, margins and Core Diagnostics turnaround. The diagnostics chain expanded its north India footprint, while maintaining robust liquidity and low debt.
Why this matters
The outlook upgrade, alongside reaffirmed AA- and A1+ ratings, strengthens the investment case for Metropolis through improving earnings quality, low leverage and strong liquidity.
What to watch
- Quarterly organic revenue growth relative to the diagnostics-industry growth rate.
- EBITDA margin progression and evidence that Core Diagnostics has reached sustained profitability.
- Net debt, lease-adjusted leverage, free-cash-flow conversion and liquidity coverage.
- Pace, cost and utilization of North India expansion.
- Changes in test pricing, competitive intensity and government or insurer reimbursement policies.